Spots Global Cancer Trial Database for A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma
Official Title: A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-BCMA Allogeneic CRISPR-Cas9-Engineered T Cells (CTX120) in Subjects With Relapsed or Refractory Multiple Myeloma
Study ID: NCT04244656
Conditions
Interventions
Study Description
Brief Summary: This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and efficacy of CTX120 in subjects with relapsed or refractory multiple myeloma.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Chicago, Chicago, Illinois, United States
Oregon Health and Science University, Portland, Oregon, United States
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Institut Catala d'Oncologia Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
Universidad de Navarra, Pamplona, Navarra, Spain
Hospital Universitario de Salamanca, Salamanca, , Spain
Contact Details
Name: Annie Weaver, PhD
Affiliation: CRISPR Therapeutics
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
